Candidiasis - Pipeline Review, Q1 2011

Date: March 1, 2011
Pages: 36
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Brief Review
Delivery: E-mail Delivery (PDF)
ID: C92F4BD8A2AEN
Leaflet:

Download PDF Leaflet

Candidiasis - Pipeline Review, Q1 2011
Candidiasis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Candidiasis - Pipeline Review, Q1 2011', provides an overview of the Candidiasis therapeutic pipeline. This report provides information on the therapeutic development for Candidiasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Candidiasis. 'Candidiasis - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Candidiasis.
  • A review of the Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Candidiasis pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Candidiasis.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Candidiasis therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Candidiasis Overview
Therapeutics Development
An Overview of Pipeline Products for Candidiasis
Candidiasis Therapeutics under Development by Companies
Candidiasis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Candidiasis Therapeutics - Products under Development by Companies
Candidiasis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Candidiasis Therapeutics Development
BioDelivery Sciences International, Inc.
Almirall, S.A.
Pevion Biotech Ltd
Evolva SA
Ferrer Internacional S.A.
Candidiasis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Universities/Institutes
Anidulafungin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anidulafungin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Caspofungin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lavender Vaginal Cream - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Candidiasis Therapeutics - Discontinued Products
Candidiasis - Featured News
Nov 11, 2010: Pevion Announces Positive Preliminary Results From Phase I Study Of PEV7 In Recurrent Vulvovaginal Candidiasis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Candidiasis, Q1 2011
Products under Development for Candidiasis – Comparative Analysis, Q1 2011
Comparative Analysis by Late Stage Development, Q1 2011
Comparative Analysis by Mid Clinical Stage Development, Q1 2011
Comparative Analysis by Early Clinical Stage Development, Q1 2011
Comparative Analysis by Pre-Clinical Stage Development, Q1 2011
BioDelivery Sciences International, Inc., 2011
Almirall, S.A., 2011
Pevion Biotech Ltd, 2011
Evolva SA, 2011
Ferrer Internacional S.A., 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Discontinued Products

LIST OF FIGURES

Number of Products under Development for Candidiasis, Q1 2011
Products under Development for Candidiasis – Comparative Analysis, Q1 2011
Products under Development by Companies, Q1 2011
Products under Investigation by Universities/Institutes, Q1 2011
Late Stage Products, Q1 2011
Mid Clinical Stage Products, Q1 2011
Early Clinical Stage Products, Q1 2011
Pre-Clinical Stage Products, Q1 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Route of Administration, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Assessment by Stage and Molecule Type, Q1 2011
Candidiasis - Pipeline Review, Q4 2010 US$ 500.00 Dec, 2010 · 33 pages
Vulvovaginal Candidiasis - Pipeline Review, Q1 2011 US$ 500.00 Jan, 2011 · 21 pages
Vulvovaginal Candidiasis - Pipeline Review, Q3 2011 US$ 500.00 Jul, 2011 · 34 pages
Candidiasis - Pipeline Review, H2 2014 US$ 2,000.00 Sep, 2014 · 105 pages

Ask Your Question

Candidiasis - Pipeline Review, Q1 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: